Viveve Medical (VIVE) Receives Buy Rating from Mizuho

Mizuho restated their buy rating on shares of Viveve Medical (NASDAQ:VIVE) in a research note released on Thursday morning. Mizuho currently has a $10.00 price objective on the stock.

VIVE has been the topic of several other research reports. ValuEngine downgraded Viveve Medical from a sell rating to a strong sell rating in a report on Friday, December 1st. Northland Securities initiated coverage on Viveve Medical in a research note on Friday, January 5th. They set an outperform rating and a $8.00 target price on the stock. Ladenburg Thalmann Financial Services reaffirmed a buy rating on shares of Viveve Medical in a research note on Thursday, January 4th. Finally, Cowen set a $11.00 target price on Viveve Medical and gave the company a buy rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $10.00.

Shares of Viveve Medical (VIVE) traded up $0.03 during midday trading on Thursday, hitting $4.27. The company had a trading volume of 39,509 shares, compared to its average volume of 156,637. The company has a market cap of $83.53 and a P/E ratio of -1.99. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72.

Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The company had revenue of $4.07 million during the quarter, compared to the consensus estimate of $4.10 million. Viveve Medical had a negative return on equity of 275.77% and a negative net margin of 257.58%. The company’s revenue for the quarter was up 120.1% on a year-over-year basis. During the same period last year, the business posted ($0.46) EPS. equities research analysts forecast that Viveve Medical will post -2.05 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in VIVE. Vanguard Group Inc. raised its stake in shares of Viveve Medical by 135.4% in the 2nd quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock worth $3,232,000 after buying an additional 258,912 shares in the last quarter. RTW Investments LP raised its stake in shares of Viveve Medical by 18.8% in the 3rd quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after buying an additional 233,585 shares in the last quarter. State Street Corp bought a new stake in shares of Viveve Medical in the 2nd quarter worth $1,282,000. Northern Trust Corp bought a new stake in shares of Viveve Medical in the 2nd quarter worth $1,169,000. Finally, ING Groep NV raised its stake in shares of Viveve Medical by 93.7% in the 3rd quarter. ING Groep NV now owns 325,000 shares of the company’s stock worth $1,703,000 after buying an additional 157,200 shares in the last quarter. 66.89% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Viveve Medical (VIVE) Receives Buy Rating from Mizuho” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/02/viveve-medical-vive-receives-buy-rating-from-mizuho-2.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply